您的位置: 首页 > 农业专利 > 详情页

ЗАМЕЩЕННЫЕ ПИРИМИДИНИЛПИРРОЛЫ, АКТИВНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ
专利权人:
NERVIANO MEDIKAL SAJENSIZ S.R.L.
发明人:
BRASKA Mariya Gabriella,БРАСКА Мария Габриелла,BANDERA Titsiano,БАНДЬЕРА Тициано,BERTRAN Dzhej Aaron,БЕРТРАН Джей Аарон,NOKKI Paola,НЬОККИ Паола,MIRITSTSI Danilo,МИРИЦЦИ Данило,NEZI Marchella,НЕЗИ Мар
申请号:
RU2013151174
公开号:
RU0002621732C2
申请日:
2012.04.05
申请国别(地区):
RU
年份:
2017
代理人:
摘要:
FIELD: chemistry.SUBSTANCE: substituted pyrimidinyl pyrrole compounds or pharmaceutically acceptable salts thereof are selected from the group consisting of 5-(2-aminopyrimidin-4-yl)-2-[2-chloro-5-(trifluoromethyl) phenyl]-1H-pyrrole-3-carboxamide, 5-(2-aminopyrimidin-4-yl)-2-(2,5-dichlorophenyl)-1H-pyrrole-3-carboxamide, 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1H-pyrrole-3-carboxamide, 5-(2-minopyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide, 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-N-methyl-1H-pyrrole-3-carboxamide, 5-(2-aminopyrimidin-4-yl)-2-(5 chloro-2-ethylphenyl)-N-ethyl-1H-pyrrole-3-carboxamide, 5-(2-aminopyrimidin-4-yl)-2-[2-chloro-5-(trifluoromethyl)phenyl]-N-methyl-1H-pyrrole-3-carboxamide, 2-(5-chloro-2-methylphenyl)-5-[2-(methylamino)pyrimidin-4-yl]-1H-pyrrole-3-carboxamide and 5-(2-aminopyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-N-methyl-1H-pyrrole-3-carboxamide. The invention also relates to versions of the method for preparation of these compounds. For example, the method may include the steps (1): metal-catalyzed coupling reaction of a halogenated derivative of formulawith a substituted phenylboronic acid of formulaor henylboronic acid ester of formula,(2) alkaline hydrolysis of the obtained carboxylic acid ester of formula(3) amidation of the obtained carboxylic acid ester of formulaby a reaction with a derivative of formula (VI) NHR8R9, to obtain a compound of formulawherein R1, R2, R3, R4, R8 and R9 values are given in the claims, and R12 is hydrogen and if desired, convertion of a compound of formula (I) to a pharmaceutically acceptable salt or salt convertion to the free compound (I). Method versions include amidation of the carboxylic acid ester of formula (IV) without carboxylic acid (V) isolation or direct preparation of formula I compound without isolation of the intermediate compound of formula (IV) and (V). To prepare the formula I compound, where R12 is hydrogen, the meth
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充